The Role of Variants Regulating Metformin Transport and Action in Women with Polycystic Ovary Syndrome

References

• Chang RJ , NakamuraRM , JuddHL , KaplanSA . Insulin resistance in nonobese patients with polycystic ovarian disease . J. Clin. Endocrinol. Metab.57 ( 2 ), 356 – 359 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Dunaif A , SegalKR , FutterweitW , DobrjanskyA . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome . Diabetes38 ( 9 ), 1165 – 1174 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Acbay O , GundogduS . Can metformin reduce insulin resistance in polycystic ovary syndrome?Fertil. Steril.65 ( 5 ), 946 – 949 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA , CavaghanMK , ImperialJ , SturisJ , RosenfieldRL , PolonskyKS . Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome . J. Clin. Endocrinol. Metab.82 ( 2 ), 524 – 530 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Pau CT , KeefeC , DuranJ , WeltCK . Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study . J. Clin. Endocrinol. Metab.99 ( 5 ), 1870 – 1878 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E , KouliC , TsianateliT , BergieleA . Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome . Eur. J. Endocrinol.138 ( 3 ), 269 – 274 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Essah PA , ApridonidzeT , IuornoMJ , NestlerJE . Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome . Fertil. Steril.86 ( 1 ), 230 – 232 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Fleming R , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial . J. Clin. Endocrinol. Metab.87 ( 2 ), 569 – 574 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Moghetti P , CastelloR , NegriCet al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 month trial, followed by open, long-term clinical evaluation . J. Clin. Endocrinol. Metab.85 ( 1 ), 139 – 146 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Tang T , LordJM , NormanRJ , YasminE , BalenAH . Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility . Cochrane Database Syst. Rev.5 , CD003053 ( 2012 ).
   Google Scholar
• Becker ML , VisserLE , Van SchaikRH , HofmanA , UitterlindenAG , StrickerBH . Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response . Pharmacogenet. Genomics20 ( 1 ), 38 – 44 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Chen Y , LiS , BrownCet al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin . Pharmacogenet. Genomics19 ( 7 ), 497 – 504 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Shu Y , BrownC , CastroRAet al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics . Clin. Pharmacol. Ther.83 ( 2 ), 273 – 280 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ha Choi J , Wah YeeS , KimMJet al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1 . Pharmacogenet. Genomics19 ( 10 ), 770 – 780 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Meyer Zu Schwabedissen HE , VerstuyftC , KroemerHK , BecquemontL , KimRB . Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms . Am. J. Physiol. Renal Physiol.298 ( 4 ), F997 – F1005 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Genotype-Tissue Expression Portal (GTex) . www.gtexportal.org/home/ .
   Google Scholar
• Tkac I , KlimcakovaL , JavorskyMet al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in Type 2 diabetes . Diabetes Obes. Metab.15 ( 2 ), 189 – 191 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Becker ML , VisserLE , Van SchaikRH , HofmanA , UitterlindenAG , StrickerBH . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus . Pharmacogenomics J.9 ( 4 ), 242 – 247 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kang HJ , SongIS , ShinHJet al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population . Drug Metab. Dispos.35 ( 4 ), 667 – 675 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Wang ZJ , YinOQ , TomlinsonB , ChowMS . OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine . Pharmacogenet. Genomics18 ( 7 ), 637 – 645 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhou K , DonnellyLA , KimberCHet al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study . Diabetes58 ( 6 ), 1434 – 1439 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gambineri A , TomassoniF , GaspariniDIet al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome . J. Clin. Endocrinol. Metab.95 ( 10 ), E204 – E208 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Diaz M , Lopez-BermejoA , Sanchez-InfantesD , BassolsJ , De ZegherF , IbanezL . Responsiveness to metformin in girls with androgen excess: collective influence of genetic polymorphisms . Fertil. Steril.96 ( 1 ), 208e202 – 213e202 ( 2011 ).
   Web of Science ®Google Scholar
• Taylor AE , MccourtB , MartinKAet al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome . J. Clin. Endocrinol. Metab.82 ( 7 ), 2248 – 2256 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Welt CK , ArasonG , GudmundssonJAet al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations . J. Clin. Endocrinol. Metab.91 ( 11 ), 4361 – 4368 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Azziz R , HincapieLA , KnochenhauerES , DewaillyD , FoxL , BootsLR . Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study . Fertil. Steril.72 ( 5 ), 915 – 925 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Welch S , GebhartSS , BergmanRN , PhillipsLS . Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects . J. Clin. Endocrinol. Metab.71 ( 6 ), 1508 – 1518 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Legro RS , BarnhartHX , SchlaffWDet al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome . N. Engl. J. Med.356 ( 6 ), 551 – 566 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Becker ML , VisserLE , Van SchaikRH , HofmanA , UitterlindenAG , StrickerBH . Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study . Diabetes58 ( 3 ), 745 – 749 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Christensen MM , Brasch-AndersenC , GreenHet al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c . Pharmacogenet. Genomics21 ( 12 ), 837 – 850 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jablonski KA , McateerJB , De BakkerPIet al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program . Diabetes59 ( 10 ), 2672 – 2681 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Shu Y , SheardownSA , BrownCet al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action . J. Clin. Invest.117 ( 5 ), 1422 – 1431 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Toyama K , YonezawaA , MasudaSet al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis . Br. J. Pharmacol.166 ( 3 ), 1183 – 1191 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Pacini G , BergmanRN . MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test . Comput. Methods Programs Biomed.23 ( 2 ), 113 – 122 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Barrett JC , FryB , MallerJ , DalyMJ . Haploview: analysis and visualization of LD and haplotype maps . Bioinformatics21 ( 2 ), 263 – 265 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Buse JB , DefronzoRA , RosenstockJet al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies . Diabetes Care39 ( 2 ), 198 – 205 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Shu Y , LeabmanMK , FengBet al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 . Proc. Natl Acad. Sci. USA100 ( 10 ), 5902 – 5907 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Kahn BB , AlquierT , CarlingD , HardieDG . AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism . Cell Metab.1 ( 1 ), 15 – 25 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• El-Mir MY , NogueiraV , FontaineE , AveretN , RigouletM , LeverveX . Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I . J. Biol. Chem.275 ( 1 ), 223 – 228 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Foretz M , HebrardS , LeclercJet al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state . J. Clin. Invest.120 ( 7 ), 2355 – 2369 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hirsch A , HahnD , KempnaPet al. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain . Endocrinology153 ( 9 ), 4354 – 4366 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Christensen MM , PedersenRS , StageTBet al. A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin . Pharmacogenet. Genomics23 ( 10 ), 526 – 534 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chen S , ZhouJ , XiMet al. Pharmacogenetic variation and metformin response . Curr. Drug Metab.14 ( 10 ), 1070 – 1082 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Zhou M , XiaL , WangJ . Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine . Drug Metab. Dispos.35 ( 10 ), 1956 – 1962 ( 2007 ).
   PubMed Web of Science ®Google Scholar